



Inventors

George Pettit

Regents Professor
Department of Chemistry
and Biochemistry
Arizona State University

Robin Pettit

Rui Tan

Song Feng

Thomas Smith

Research Professor
Department of Chemistry
and Biochemistry
Arizona State University

Intellectual Property

Status:

Patent Pending

Contact

Jack Geltosky, PhD

Senior Vice President
Business Development, Life
Sciences

Arizona Technology
Enterprises, LLC (AzTE)

P: 480.884.1989

F: 480.884.1984

JGELTSKY@AZTE.COM

HEALTHSCIENCES@AZTE.COM

Cyclodepsipeptides compounds presenting anti-cancer and anti-infective activity, and their synthesis.

AzTE Case # M07-064

Invention Description

Kitasatospora sp. produces a variety of metabolites with anti-cancer activity, such as the cyclodepsipeptide respirantin.

Researchers at Arizona State have isolated other related molecules with anti-cancer and anti-microbial activities: kitastatin 1 and a valeryl modification of respirantin.

These three compounds exhibit potent anti- cancer cell growth properties ($GI_{50} \sim 0.0006 \mu\text{g/mL}$). These compounds also have potential anti-infective activities.

Researchers at ASU have also realized the total synthesis of the respirantin compound. This approach should offer ready access to the scale-up synthesis of respirantin, kitastatin and a variety of their structural analogs.

Potential Applications

- **Anti-cancer therapeutic agents**
- **Anti-microbial and anti-fungal agents**

Benefits and Advantages

- **Diversity** – Discovery of a whole class of structurally unique and powerful cancer cell growth inhibitors, which properties have never been reported. Compounds also present potential anti-microbial/anti-fungal activities.
- **Synthesis** – These compounds are synthetically available.
- **Efficacy** – The new compounds display an impressive spectrum of activity against a panel of human cancer cell lines. Kitastatin 1 showed a special selectivity against the pancreas BXP-3 human cancer cell line.